Innoventric Trillium™ Stent Graft First-in-Human (FIH) Study

Launched by INNOVENTRIC LTD · Feb 26, 2020

Keywords

ClinConnect Summary

The Innoventric Trillium™ Stent Graft study is a research trial aimed at testing a new device designed for patients with tricuspid regurgitation (TR), a condition where the heart's tricuspid valve doesn’t close properly, leading to blood flow issues. This study will involve 20 participants from eight different medical centers. To qualify for the study, patients must be over 40 years old, have severe TR that causes symptoms even after medical treatment, and be willing to follow the study requirements.

Participants will undergo the procedure and will be monitored at various intervals, including one month, three months, six months, one year, and up to three years afterward. This helps the researchers understand how safe and effective the device is over time. It’s important to note that patients who have certain heart conditions or other serious health issues will not be eligible for this trial. The goal is to see if this innovative stent graft can improve the quality of life for those suffering from severe TR.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• Enrolled patients must meet ALL the following criteria:
• • 1. Age \>40 (no upper limit)
• • 2. Patient has clinically significant TR graded as severe based on the presence of systolic hepatic vein flow reversal, and VCW≥7mm or EROA≥40mm\^2
• • 3. Symptomatic despite medical therapy; patient must be on diuretic therapy.
• • 4. Peak central venous pressure of ≥ 15mmHg
• • 5. The local site Heart Team determines that the patient is appropriate for transcatheter tricuspid intervention
• • 6. Patient is willing and able to comply with all specified study evaluations.
• • 7. Patient has NYHA functional classification of III or IV
• • 8. Patient is not eligible for standard-of-care surgical or interventional therapy assessed by the central heart team or has refused standard-of-care surgical and interventional therapy or has received standard-of-care TR therapy and remains symptomatic
• • 9. Patient understands the nature of the study and study requirements and is willing to provide written Informed Consent prior to any study-specific procedures.
• Exclusion Criteria:
• Patients will be excluded from participation if ANY of the following criteria apply:
• 1. Echocardiographic parameters (Any of the following):
• • I. LVEF \< 20% II. Evidence of severe right ventricular dysfunction (e.g. right ventricular TAPSE \< 13.0mm) III. IVC or SVC anatomy that precludes proper device deployment and function
• • 2. Systolic Pulmonary Artery Pressure \> 70mmHg
• • 3. Severe aortic, mitral, and/or pulmonic valve stenosis and/or regurgitation
• • 4. Active endocarditis within 90 days of the scheduled implant
• • 5. Significant pericardial effusion
• • 6. Intra-cardiac masses, thrombi, or vegetation
• • 7. Thrombosis of the venous system
• • 8. Space-consuming lesion in the heart or on the valves, thrombus, or microbial colonization of the valves
• • 9. Untreated clinically significant coronary artery disease requiring immediate revascularization
• • 10. MI or known unstable angina within 30 days prior to the index procedure
• • 11. Any therapeutic invasive cardiac procedure within 30 days prior to the index procedure
• • 12. Any prior cardiac surgery, within 3 months of the index procedure
• • 13. Hemodynamic instability or treated with IV inotropes within 30 days of the index procedure
• • 14. Severe uncontrolled hypertension (SBP ≥ 180 mmHg and/or DBP ≥ 110 mm Hg)
• • 15. Severe uncontrolled hypotension (SBP≤80 mmHg and/or DBP≤40 mmHg)
• • 16. Cerebrovascular Accident (CVA) within the past 90 days
• • 17. Kidney dysfunction with estimated Glomerular Filtration Rate (eGFR) \< 30 ml/min/1.73 m\^2 or patient is on chronic dialysis
• • 18. Significant frailty (i.e. Clinical Frailty Scale© (CFS) ≥ 7) within 90 days of the scheduled implant procedure
• • 19. Chronic liver disease with a MELD score of 20 or greater
• • 20. Chronic anemia (Hb \< 9 g/L) not corrected by transfusion
• • 21. Thrombocytopenia (Platelet count\< 100,000/mm3) or thrombocytosis (Platelet count \> 750,000/mm3)
• • 22. Bleeding disorders or hypercoagulable state
• • 23. Active peptic ulcer or active gastrointestinal (GI) bleeding within 90 days of the scheduled implant
• • 24. Contraindication to anticoagulants or antiplatelet agents
• • 25. Currently or history of IV drug use
• • 26. Pregnant or lactating; or female of childbearing potential with a positive pregnancy test 24 hours before any study-related radiation exposure.
• • 27. Inability to access the femoral vein with a 24 FR guide (e.g., DVT, occluded femoral veins).
• • 28. Known allergy to stainless steel, nickel, titanium, PET or contrast agents that cannot be adequately pre-medicated.
• • 29. Known hypersensitivity or contraindication to procedural medications which cannot be adequately managed medically
• • 30. Impaired judgment
• • 31. Undergoing emergent or urgent treatment for tricuspid insufficiency
• • 32. Currently participating in another investigational drug or device study that has not completed the primary endpoint or that clinically interferes with the endpoints of this study
• • 33. Co-morbid condition(s) that, in the opinion of the Investigator, limit life expectancy to \< 12 months
• • 34. Cardiac cachexia
• • 35. In the judgment of the Investigator, co-morbid condition(s) that could limit the patient's ability to participate in the study, including compliance with follow-up requirements, or that could impact the scientific integrity of the study
• • 36. Patient is under guardianship
• • 37. Presence of any prosthetic device in the SVC or IVC (excluding pace-maker, ICD and CRT leads)
• • 38. Elevated inflammatory markers within 2 weeks of the scheduled procedure (e.g. CRP\>1.5mg/dL).